Evidence map›Paper›PMID 35760975›Full record

ArticleBreast cancer research and treatment2022

Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel.

Ciao-Sin Chen, Ellen M Lavoie Smith, Kathleen A Stringer, N Lynn Henry, Daniel L Hertz

Open access · greenAbstract readClinical Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ciao-Sin ChenDepartment of Clinical Pharmacy, University of Michigan College of Pharmacy, 428 Church St., Room 3054, Ann Arbor, MI, 48109-1065, USA.
Ellen M Lavoie SmithUniversity of Alabama at Birmingham School of Nursing, Birmingham, AL, USA.
Kathleen A StringerDepartment of Clinical Pharmacy, University of Michigan College of Pharmacy, 428 Church St., Room 3054, Ann Arbor, MI, 48109-1065, USA.
N Lynn HenryUniversity of Michigan Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA.
Daniel L HertzDepartment of Clinical Pharmacy, University of Michigan College of Pharmacy, 428 Church St., Room 3054, Ann Arbor, MI, 48109-1065, USA. DLHertz@med.umich.edu.ORCID http://orcid.org/0000-0003-0501-1035
University of Michigan · USUniversity of Alabama at Birmingham · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2M
Michigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9M
Translational Metabolomics in Critical CareR35GM136312 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KATHLEEN A STRINGER · 2020 to 2026
$2.8M
Michigan Institute for Clinical and Health Research (MCHR)KL2TR000434 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$1.7M
NCATS NIH HHS 2UL1TR000433NCATS NIH HHS KL2 TR000434NCATS NIH HHS KL2TR000434NCATS NIH HHS UL1 TR000433NCI NIH HHS P30 CA046592NCI NIH HHS P30CA046592NIGMS NIH HHS GM136312NIGMS NIH HHS R35 GM136312
6 · The paper itself

Abstract

purposeChemotherapy-induced peripheral neuropathy (CIPN) is the major treatment-limiting toxicity of paclitaxel, which predominantly presents as sensory symptoms, with motor symptoms in some patients. Differentiating CIPN into subtypes has been recommended to direct CIPN research. The objective of this study was to investigate whether sensory and motor CIPN are distinct subtypes with different predictive biomarkers in patients with breast cancer receiving paclitaxel.

methodsData were from a prospective cohort of 60 patients with breast cancer receiving up to 12 weekly infusions of 80 mg/m

resultsMore sensory than motor CIPN was found (CIPN

conclusionOur findings suggest that sensory and motor CIPN co-occur and may not have differentiating metabolic biomarkers. These findings need to be validated in larger cohorts of patients treated with paclitaxel and other neurotoxic agents to determine the optimal approach to predict, prevent, and treat CIPN and improve patients' outcomes.

Indexed as

Breast NeoplasmsPaclitaxelPeripheral Nervous System DiseasesAntineoplastic AgentsFemaleHumansProspective StudiesQuality of LifeAntineoplastic AgentsPaclitaxelChemotherapy-induced peripheral neuropathyClusteringMetabolomicsMotorPredictive biomarkersSensory

Identifiers

PMID35760975
PMCPMC9310087
OpenAlexW4283640092

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.